Precigen Investor Credits Papzimeos Launch for Strong Gains
Patient Opportunity Equity Strategy credited the drug’s launch with driving gains and pointed to cancer trials and other pipeline programs.
Key takeaways
- The strategy said Precigen shares became a 10-bagger after its late-2024 capital raise.
- The investor cited Papzimeos’ launch and upcoming cancer trial results as potential drivers.
Patient Opportunity Equity Strategy said Precigen shares have become a 10-bagger since it led the company’s capital raise in late 2024. In its third-quarter investor letter, the strategy credited the gain to the successful launch of Papzimeos.
The strategy said the drug treats recurrent respiratory papillomatosis, a disease caused by HPV. It also said the FDA recently granted platform designation to Adenoverse, the technology underlying Papzimeos, which the strategy said eases approval requirements for related treatments.
Precigen is expected to report trial results soon for head-and-neck and cervical cancer. The strategy said it expects solid results and sees potential in the company’s CAR-T program.
This article was produced with the help of AI technology. Source: Yahoo Finance